<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389207</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1470</org_study_id>
    <secondary_id>2005-004330-40</secondary_id>
    <nct_id>NCT00389207</nct_id>
  </id_info>
  <brief_title>Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults</brief_title>
  <official_title>Randomized, Open Label Study Evaluating the Lipid Profile Difference and Efficacy of a Combined Therapy Including Tenofovir, Emtricitabine + Atazanavir / r or NVP in Naive HIV - 1 Infected Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Primary purpose of this study is to compare the efficacy and safety of two different
      nevirapine (Viramune) dosing regimens (once daily (QD) and twice daily (BID) application) and
      of atazanavir/ritonavir (Reyataz/Norvir), all on an emtricitabine/tenofovir disoproxil
      fumarate (DF) (Truvada) background. Patients will receive either nevirapine (NVP) 200 mg
      twice daily, or NVP 400 mg once daily , or ritonavir-boosted atazanavir (ATZ/r), all in
      combination with emtricitabine (FTC) and tenofovir DF (TDF).

      All patients receiving NVP will start at 200 mg once daily for 2 weeks, because it has been
      demonstrated that this lead-in dosing regimen reduces the frequency of NVP-induced rash. At
      Visit 3 (Week 2), patients increase the NVP dose to either 200 mg twice daily or to 400 mg
      once daily. Patients receiving ATZ/r will be treated with ATZ 300 mg once daily, boosted by
      100 mg ritonavir (RTV) once daily. Background antiretroviral therapy for all patients
      consists of one tablet of Truvada. Treatment duration is 48 weeks (primary endpoint) with an
      extension to 144 weeks. Patients may also participate in the metabolic sub-study, comparing
      NVP and ATZ/r for signs and symptoms of lipodystrophy and serum lipid/glycaemic
      abnormalities.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Response at Week 48</measure>
    <time_frame>From baseline to Week 48</time_frame>
    <description>Treatment response is defined as a viral load (VL) &lt;50 copies/mL measured at two consecutive visits prior to Week 48 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 48.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 48 (TLOVR Algorithm)</measure>
    <time_frame>From baseline to Week 48</time_frame>
    <description>Treatment response is defined as a VL &lt;50 copies/mL measured at two consecutive visits up to Week 48 and without subsequent rebound or change of ARV therapy up to Week 48, based on time to loss of virologic response (TLOVR) algorithm, as a sensitivity analysis for the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With VL &lt; 50 Copies/ml</measure>
    <time_frame>From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT</time_frame>
    <description>VL &lt;50 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) for the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With VL &lt; 400 Copies/ml</measure>
    <time_frame>From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT</time_frame>
    <description>VL &lt;400 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ Count From Baseline</measure>
    <time_frame>From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT</time_frame>
    <description>Change in CD4+ cell count from baseline among patients on treatment at each visit, with the final visit at Week 144 or EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Framingham Score From Baseline</measure>
    <time_frame>From baseline to Weeks 48, 96 and 144/EOT</time_frame>
    <description>Change in the estimated risk of cardiovascular disease using the Framingham algorithm from baseline to after 48, 96 and 144 weeks, last observation carried forward (LOCF). The score is based on age, gender, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol and smoking status. Scores range from 0 to 21 with higher scores indicating a greater risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mental Health Summary (MHS) Score From Baseline</measure>
    <time_frame>From baseline to Weeks 48, 96 and 144/EOT</time_frame>
    <description>Quality of life (QoL) assessment by change in MHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the Medical Outcomes Study HIV Health Survey (MOS-HIV), a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The MHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Health Summary (PHS) Score From Baseline</measure>
    <time_frame>From baseline to Weeks 48, 96 and 144/EOT</time_frame>
    <description>QoL assessment by change in PHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the MOS-HIV, a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The PHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Hospitalized</measure>
    <time_frame>From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT</time_frame>
    <description>Cost effectiveness assessment by number of patients hospitalized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-scheduled Physician Visits</measure>
    <time_frame>From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT</time_frame>
    <description>Cost effectiveness assessment by number of patients with non-scheduled physician visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotypic Resistance Associated With Virologic Failure</measure>
    <time_frame>From baseline to Week 48</time_frame>
    <description>Number of treatment-emergent drug-associated substitutions in patients with virological failure up to Week 48. The total number of genotypic mutations in those patients who were virologic failures is given, not the number of patients with mutations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent AIDS-defining Illness</measure>
    <time_frame>From baseline to Week 144</time_frame>
    <description>Treatment-emergent AIDS-defining illness (tr.-emerg. AIDS-def.illness) including worsening during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent AIDS-defining Illness Leading to Death</measure>
    <time_frame>From baseline to Week 144</time_frame>
    <description>Patients with an AIDS-defining illness leading to death broken out by treatment. Statistical analysis shows time to death from AIDS-defining illness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipodystrophy</measure>
    <time_frame>From baseline to Week 144</time_frame>
    <description>Number of patients with AE lipodystrophy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Lipid Abnormalities</measure>
    <time_frame>From baseline to Week 144</time_frame>
    <description>Number of patients with AE elevated serum lipids (i.e. hypercholesterolaemia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycaemic Abnormalities</measure>
    <time_frame>From baseline to Week 144</time_frame>
    <description>Number of patients with AE elevated serum glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 96</measure>
    <time_frame>From baseline to Week 96</time_frame>
    <description>Treatment response is defined as a viral load (VL) &lt;50 copies/mL measured at two consecutive visits prior to Week 96 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 96.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 144</measure>
    <time_frame>From baseline to Week 144</time_frame>
    <description>Treatment response is defined as a viral load (VL) &lt;50 copies/mL measured at two consecutive visits prior to Week 144 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 144.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Virological Rebound With VL &gt;=50 Copies/mL After CVR (Confirmed Virological Response) at Week 24, 48, 96, 144</measure>
    <time_frame>at Week 24, 48, 96, 144</time_frame>
    <description>The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Virological Rebound With VL &gt;=400 Copies/mL After CVR at Week 24, 48, 96, 144</measure>
    <time_frame>at Week 24, 48, 96, 144</time_frame>
    <description>The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Virologic Failure at Week 48, 96, 144</measure>
    <time_frame>at Week 48, 96, 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Response (First Confirmed VL&lt;50 Copies/mL)</measure>
    <time_frame>baseline to week 144</time_frame>
    <description>Time to treatment response was defined as the time from start of treatment until the first measurement of the first confirmed virological response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Loss of Virologic Response (Rebound)</measure>
    <time_frame>Baseline to week 144</time_frame>
    <description>Time to loss of virologic response (TLOVR) was defined as the time from start of treatment to the first measurement showing VL ≥ 50 copies/mL in the first virologic rebound, after having a confirmed virological response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>baseline to week 144</time_frame>
    <description>Treatment failure is defined as the occurrence of the first of at least one of the following events: early discontinuation of trial drug, change in ARV therapy, failure to achieve an HIV RNA count &lt; 50 copies/mL up to Visit 10 (week 48) or loss of virologic response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Calculated Glomerular Filtration Rate (GFR) at Week 48, 96 and 144</measure>
    <time_frame>From baseline to Week 48, 96, 144</time_frame>
    <description>Calculations based on the MDRD algorithm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With &gt;= DAIDS Grade 2 Laboratory Abnormalities</measure>
    <time_frame>week 148</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Reporting Rash of Any Severity</measure>
    <time_frame>week 148</time_frame>
    <description>Proportion of Patients reporting rash of any severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Reporting Hepatic Events of Any Severity</measure>
    <time_frame>week 148</time_frame>
    <description>Proportion of Patients reporting hepatic events of any severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Reporting CNS (Central Nervous System) Side Effects of Any Severity</measure>
    <time_frame>week 148</time_frame>
    <description>Proportion of Patients reporting CNS (central nervous system) side effects of any severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Cholesterol Values From Baseline to Week 48, 96, 144</measure>
    <time_frame>baseline to week 48, 96, 144</time_frame>
    <description>Changes frombaseline in total cholesterol, LDL-cholesterol(LDL-c) and HDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Apolipoprotein Values From Baseline to Week 48, 96, 144</measure>
    <time_frame>baseline to week 48, 96, 144</time_frame>
    <description>Changes frombaseline apolipoprotein A1 &amp; B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of hsCRP From Baseline to Week 48, 96, 144</measure>
    <time_frame>baseline to week 48, 96, 144</time_frame>
    <description>Change of hsCRP from baseline to week 48, 96, 144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Total Triglycerides From Baseline to Week 48, 96, 144</measure>
    <time_frame>baseline to week 48, 96, 144</time_frame>
    <description>Change of total triglycerides from baseline to week 48, 96, 144</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Total Cholesterol to HDL-cholesterol Ratio From Baseline to Week 48, 96, 144</measure>
    <time_frame>baseline to week 48, 96, 144</time_frame>
    <description>Change of Total cholesterol to HDL-cholesterol ratio from baseline to week 48, 96, 144</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">576</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>NVP bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nevirapine (NVP) 200 mg BID in combination with emtricitabine (FTC) and tenofovir DF (TDF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nevirapine (NVP) 400 mg QD in combination with emtricitabine (FTC) and tenofovir DF (TDF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATZ/r</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ritonavir-boosted atazanavir in combination with emtricitabine (FTC) and tenofovir DF (TDF)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nevirapine bid</intervention_name>
    <description>nevirapine twice daily</description>
    <arm_group_label>NVP bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nevirapine qd</intervention_name>
    <description>nevirapine once daily</description>
    <arm_group_label>NVP qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir</intervention_name>
    <description>atazanavir once daily</description>
    <arm_group_label>ATZ/r</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Inclusion Criteria:

          1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local
             regulatory requirements prior to trial participation

          2. HIV-1-infected males or females &gt;= 18 years of age with positive serology confirmed by
             Western blot

          3. No previous antiretroviral treatment (of more than 7 days)

          4. Males with CD4+ counts of &lt; 400 cells/mm3 and females with CD4+ counts of &lt; 250
             cells/mm3

          5. NVP- and ATZ/r susceptibility based on HIV-1 genotypic resistance report

          6. Adequate renal function defined as a calculated creatinine clearance (CLCr) &gt;= 50
             ml/min according to the Cockcroft-Gault formula

          7. Karnofsky score &gt;= 70

          8. Acceptable medical history, as assessed by the investigator

        Exclusion criteria:

        Exclusion Criteria:

          1. Active drug abuse or chronic alcoholism at the investigator's discretion

          2. Hepatic cirrhosis stage Child-Pugh B or C

          3. Female patients of child-bearing potential who:

               -  have a positive serum pregnancy test at screening or during the study,

               -  are breast feeding,

               -  are planning to become pregnant,

               -  are not willing to use a barrier method of contraception, or are not willing to
                  use methods of contraception other than ethinyl estradiol containing oral
                  contraceptives

          4. Laboratory parameters Division of Acquired Immunodeficiency Syndrome (DAIDS) &gt; grade 2
             (triglycerides &gt; DAIDS grade 3; total cholesterol no restrictions)

          5. Active hepatitis B or C disease, defined as HBsAg-positive or Hepatitis C-Virus-Ribo
             Nucleic Acid (HCV-RNA)- positive with Aspartate Transaminase/Alanine Transaminase
             (AST/ALT) &gt; 2.5x Upper Limit of Normal (ULN) (DAIDS grade 1)

          6. Hypersensitivity to any ingredients of the test products

          7. Have therapy with nephrotoxic drugs (e.g., aminoglycosides, amphotericin B,
             vancomycin, cidofovir, foscarnet, cisplatin, pentamidine, tacrolimus, cyclosporine) or
             potential competitors of renal excretion (e.g., cidofovir, acyclovir, valacyclovir,
             ganciclovir, valganciclovir, probenecid, high-dose non-steroidal anti-inflammatory
             drugs (i.e., ibuprofen)) within 3 months prior to study screening or are expected to
             receive these during the study

          8. Patients who are receiving other concomitant treatments which are not permitted

          9. Use of other investigational medications within 30 days before study entry or during
             the trial

         10. Use of immunomodulatory drugs within 30 days before study entry or during the trial
             (e.g., interferon, cyclosporin, hydroxyurea, interleukin 2, chronic treatment with
             prednisone)

         11. Patients with Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi's
             Sarcoma (KS), and/or any lymphoma

         12. Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment
             for at least 12 weeks at screening visit

         13. Patients who are receiving systemic treatment for malignant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1100.1470.54004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.54003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.54001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg/Breisgau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49000 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.49032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.39012 Ospedale Sant'Anna</name>
      <address>
        <city>Como</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.39010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torrette Di Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.55006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.55004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Col Obregón</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.55008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Col. Los Filtros, San Luis Potosí</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.55001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Col. Toriello Guerra</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.55007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara Jal.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.55003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tlalpan-México D,F</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chorzow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.35102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cascais</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.35101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.35103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.40001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.40002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alcalá de Henares (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sabadell (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Sebastian</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.34011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.41004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.41001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.41003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.41002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.44004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1470.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2006</study_first_submitted>
  <study_first_submitted_qc>October 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2006</study_first_posted>
  <results_first_submitted>January 13, 2012</results_first_submitted>
  <results_first_submitted_qc>February 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2012</results_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nevirapine QD</title>
          <description>Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)</description>
        </group>
        <group group_id="P2">
          <title>Nevirapine BID</title>
          <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
        </group>
        <group group_id="P3">
          <title>Atazanvir/Ritonavir</title>
          <description>Atazanvir 300mg QD boosted by ritonavir 100mg QD (ATZ/r) on a background of the fixed combination Truvada®</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="188">3 patients were randomized to NVP QD but not treated and so not part of the Full Analysis Set (FAS)</participants>
                <participants group_id="P2" count="188">4 patients were randomized to NVP BID but not treated and so are not part of the FAS</participants>
                <participants group_id="P3" count="193"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nevirapine QD</title>
          <description>Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)</description>
        </group>
        <group group_id="B2">
          <title>Nevirapine BID</title>
          <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
        </group>
        <group group_id="B3">
          <title>Atazanvir/Ritonavir</title>
          <description>ATZ/r on a background of the fixed combination Truvada®</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="188"/>
            <count group_id="B2" value="188"/>
            <count group_id="B3" value="193"/>
            <count group_id="B4" value="569"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.4" spread="9.7"/>
                    <measurement group_id="B2" value="40.0" spread="10.5"/>
                    <measurement group_id="B3" value="37.6" spread="9.5"/>
                    <measurement group_id="B4" value="38.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="162"/>
                    <measurement group_id="B4" value="477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HIV viral load category</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Baseline HIV viral load ≤ 100,000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline HIV viral load &gt; 100,000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline log10 HIV viral load</title>
          <description>185 NVP QD patients, 188 NVP BID patients and 192 ATZ/R patients had data</description>
          <units>log 10 Copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.1" spread="0.7"/>
                    <measurement group_id="B2" value="5.1" spread="0.6"/>
                    <measurement group_id="B3" value="5.1" spread="0.7"/>
                    <measurement group_id="B4" value="5.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline CD4+ cell count</title>
          <description>185 NVP QD patients, 188 NVP BID patients and 192 ATZ/R patients had data</description>
          <units>Cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183.3" spread="95.5"/>
                    <measurement group_id="B2" value="202.9" spread="93.6"/>
                    <measurement group_id="B3" value="193.2" spread="95.8"/>
                    <measurement group_id="B4" value="193.2" spread="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Response at Week 48</title>
        <description>Treatment response is defined as a viral load (VL) &lt;50 copies/mL measured at two consecutive visits prior to Week 48 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 48.</description>
        <time_frame>From baseline to Week 48</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O4">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 48</title>
          <description>Treatment response is defined as a viral load (VL) &lt;50 copies/mL measured at two consecutive visits prior to Week 48 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 48.</description>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="376"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="124"/>
                    <measurement group_id="O3" value="250"/>
                    <measurement group_id="O4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="126"/>
                    <measurement group_id="O4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin 12% (or 0.12 as proportion)</non_inferiority_desc>
            <p_value>0.684</p_value>
            <p_value_desc>Test for superiority following confirmation of non-inferiority</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for screening VL and CD4+ categories (only 373 NVP patients due to empty cells)</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.016</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.062</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin 12% (or 0.12 as proportion)</non_inferiority_desc>
            <p_value>0.584</p_value>
            <p_value_desc>Test for superiority following confirmation of non-inferiority</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Analysis controlling for screening viral load and CD4+ count categories. N=186 NVP QD patients and N=193 ATZ/r patients.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.065</ci_lower_limit>
            <ci_upper_limit>0.115</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin 12% (or 0.12 as proportion)</non_inferiority_desc>
            <p_value>0.855</p_value>
            <p_value_desc>Test for superiority following confirmation of non-inferiority</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Analysis controlling for screening viral load and CD4+ count categories. N=187 NVP QD patients and N=193 ATZ/r patients.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.009</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.084</ci_lower_limit>
            <ci_upper_limit>0.101</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 48 (TLOVR Algorithm)</title>
        <description>Treatment response is defined as a VL &lt;50 copies/mL measured at two consecutive visits up to Week 48 and without subsequent rebound or change of ARV therapy up to Week 48, based on time to loss of virologic response (TLOVR) algorithm, as a sensitivity analysis for the primary analysis.</description>
        <time_frame>From baseline to Week 48</time_frame>
        <population>FAS but numbers are reduced as indicated due to empty cells in analysis adjusting for baseline categories</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 48 (TLOVR Algorithm)</title>
          <description>Treatment response is defined as a VL &lt;50 copies/mL measured at two consecutive visits up to Week 48 and without subsequent rebound or change of ARV therapy up to Week 48, based on time to loss of virologic response (TLOVR) algorithm, as a sensitivity analysis for the primary analysis.</description>
          <population>FAS but numbers are reduced as indicated due to empty cells in analysis adjusting for baseline categories</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261"/>
                    <measurement group_id="O2" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin 12% (or 0.12 as proportion)</non_inferiority_desc>
            <p_value>0.321</p_value>
            <p_value_desc>Test for superiority following confirmation of non-inferiority</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Analysis controlling for screening viral load and CD4+ count categories. N=373 NVP QD patients and N=193 ATZ/r patients.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.038</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.112</ci_lower_limit>
            <ci_upper_limit>0.037</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With VL &lt; 50 Copies/ml</title>
        <description>VL &lt;50 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) for the patient</description>
        <time_frame>From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT</time_frame>
        <population>FAS with varying numbers missing or not on treatment per visit</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With VL &lt; 50 Copies/ml</title>
          <description>VL &lt;50 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) for the patient</description>
          <population>FAS with varying numbers missing or not on treatment per visit</population>
          <units>Proportion of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.107"/>
                    <measurement group_id="O2" value="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.304"/>
                    <measurement group_id="O2" value="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.515"/>
                    <measurement group_id="O2" value="0.412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.842"/>
                    <measurement group_id="O2" value="0.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.907"/>
                    <measurement group_id="O2" value="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.931"/>
                    <measurement group_id="O2" value="0.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.959"/>
                    <measurement group_id="O2" value="0.901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.965"/>
                    <measurement group_id="O2" value="0.915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.972"/>
                    <measurement group_id="O2" value="0.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98"/>
                    <measurement group_id="O2" value="0.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.964"/>
                    <measurement group_id="O2" value="0.968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.976"/>
                    <measurement group_id="O2" value="0.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.971"/>
                    <measurement group_id="O2" value="0.947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;50 copies /mL at Week 144/EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.952"/>
                    <measurement group_id="O2" value="0.929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With VL &lt; 400 Copies/ml</title>
        <description>VL &lt;400 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT)</description>
        <time_frame>From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT</time_frame>
        <population>FAS with varying numbers missing or not on treatment per visit</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With VL &lt; 400 Copies/ml</title>
          <description>VL &lt;400 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT)</description>
          <population>FAS with varying numbers missing or not on treatment per visit</population>
          <units>Proportion of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.365"/>
                    <measurement group_id="O2" value="0.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.714"/>
                    <measurement group_id="O2" value="0.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.856"/>
                    <measurement group_id="O2" value="0.834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.924"/>
                    <measurement group_id="O2" value="0.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.968"/>
                    <measurement group_id="O2" value="0.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.985"/>
                    <measurement group_id="O2" value="0.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.993"/>
                    <measurement group_id="O2" value="0.988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.996"/>
                    <measurement group_id="O2" value="0.988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.988"/>
                    <measurement group_id="O2" value="0.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000"/>
                    <measurement group_id="O2" value="0.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.996"/>
                    <measurement group_id="O2" value="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000"/>
                    <measurement group_id="O2" value="0.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.996"/>
                    <measurement group_id="O2" value="0.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion with VL&lt;400 copies /mL at Week 144/EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.991"/>
                    <measurement group_id="O2" value="0.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4+ Count From Baseline</title>
        <description>Change in CD4+ cell count from baseline among patients on treatment at each visit, with the final visit at Week 144 or EOT</description>
        <time_frame>From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT</time_frame>
        <population>FAS with varying numbers missing or not on treatment per visit</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4+ Count From Baseline</title>
          <description>Change in CD4+ cell count from baseline among patients on treatment at each visit, with the final visit at Week 144 or EOT</description>
          <population>FAS with varying numbers missing or not on treatment per visit</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in CD4+ count to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" spread="93.5"/>
                    <measurement group_id="O2" value="86.1" spread="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4+ count to Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.6" spread="108.0"/>
                    <measurement group_id="O2" value="98.0" spread="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4+ count to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.3" spread="113.9"/>
                    <measurement group_id="O2" value="110.9" spread="111.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4+ count to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.4" spread="114.9"/>
                    <measurement group_id="O2" value="133.8" spread="110.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4+ count to Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.1" spread="123.0"/>
                    <measurement group_id="O2" value="163.4" spread="119.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4+ count to Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.2" spread="127.0"/>
                    <measurement group_id="O2" value="183.6" spread="121.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4+ count to Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.8" spread="129.6"/>
                    <measurement group_id="O2" value="208.2" spread="144.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4+ count to Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213.7" spread="165.7"/>
                    <measurement group_id="O2" value="231.9" spread="165.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4+ count to Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.0" spread="147.1"/>
                    <measurement group_id="O2" value="246.4" spread="149.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4+ count to Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.7" spread="133.5"/>
                    <measurement group_id="O2" value="251.6" spread="149.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4+ count to Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231.2" spread="148.9"/>
                    <measurement group_id="O2" value="267.2" spread="161.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4+ count to Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231.3" spread="147.6"/>
                    <measurement group_id="O2" value="269.2" spread="169.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4+ count to Week 132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.4" spread="164.8"/>
                    <measurement group_id="O2" value="281.3" spread="147.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4+ count to Week 144/EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251.0" spread="151.6"/>
                    <measurement group_id="O2" value="285.8" spread="164.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Framingham Score From Baseline</title>
        <description>Change in the estimated risk of cardiovascular disease using the Framingham algorithm from baseline to after 48, 96 and 144 weeks, last observation carried forward (LOCF). The score is based on age, gender, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol and smoking status. Scores range from 0 to 21 with higher scores indicating a greater risk.</description>
        <time_frame>From baseline to Weeks 48, 96 and 144/EOT</time_frame>
        <population>FAS with varying numbers missing</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Framingham Score From Baseline</title>
          <description>Change in the estimated risk of cardiovascular disease using the Framingham algorithm from baseline to after 48, 96 and 144 weeks, last observation carried forward (LOCF). The score is based on age, gender, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol and smoking status. Scores range from 0 to 21 with higher scores indicating a greater risk.</description>
          <population>FAS with varying numbers missing</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Framingham score to Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="2.79"/>
                    <measurement group_id="O2" value="0.66" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Framingham score to Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="3.15"/>
                    <measurement group_id="O2" value="1.19" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Framingham score to Week 144/EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="3.40"/>
                    <measurement group_id="O2" value="0.82" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mental Health Summary (MHS) Score From Baseline</title>
        <description>Quality of life (QoL) assessment by change in MHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the Medical Outcomes Study HIV Health Survey (MOS-HIV), a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The MHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL.</description>
        <time_frame>From baseline to Weeks 48, 96 and 144/EOT</time_frame>
        <population>FAS with varying numbers missing</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mental Health Summary (MHS) Score From Baseline</title>
          <description>Quality of life (QoL) assessment by change in MHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the Medical Outcomes Study HIV Health Survey (MOS-HIV), a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The MHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL.</description>
          <population>FAS with varying numbers missing</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in MHS score to Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" spread="9.31"/>
                    <measurement group_id="O2" value="4.52" spread="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in MHS score to Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.10" spread="9.75"/>
                    <measurement group_id="O2" value="4.89" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in MHS score to Week 144/EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76" spread="10.33"/>
                    <measurement group_id="O2" value="4.70" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Health Summary (PHS) Score From Baseline</title>
        <description>QoL assessment by change in PHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the MOS-HIV, a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The PHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL.</description>
        <time_frame>From baseline to Weeks 48, 96 and 144/EOT</time_frame>
        <population>FAS with varying numbers missing</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Health Summary (PHS) Score From Baseline</title>
          <description>QoL assessment by change in PHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the MOS-HIV, a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The PHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL.</description>
          <population>FAS with varying numbers missing</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in PHS score to Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="7.77"/>
                    <measurement group_id="O2" value="3.35" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in PHS score to Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="7.83"/>
                    <measurement group_id="O2" value="3.00" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in PHS score to Week 144/EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="8.77"/>
                    <measurement group_id="O2" value="3.35" spread="8.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Hospitalized</title>
        <description>Cost effectiveness assessment by number of patients hospitalized</description>
        <time_frame>From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT</time_frame>
        <population>FAS with varying numbers missing</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Hospitalized</title>
          <description>Cost effectiveness assessment by number of patients hospitalized</description>
          <population>FAS with varying numbers missing</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number hospitalized between baseline and Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number hospitalized between Week 24 and Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number hospitalized between Week 48 and Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number hospitalized between Week 96 and Wk 144/EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-scheduled Physician Visits</title>
        <description>Cost effectiveness assessment by number of patients with non-scheduled physician visits</description>
        <time_frame>From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT</time_frame>
        <population>FAS with varying numbers missing</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Non-scheduled Physician Visits</title>
          <description>Cost effectiveness assessment by number of patients with non-scheduled physician visits</description>
          <population>FAS with varying numbers missing</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number between baseline and Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number between Week 24 and Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number between Week 48 and Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number between Week 96 and Wk 144/EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genotypic Resistance Associated With Virologic Failure</title>
        <description>Number of treatment-emergent drug-associated substitutions in patients with virological failure up to Week 48. The total number of genotypic mutations in those patients who were virologic failures is given, not the number of patients with mutations.</description>
        <time_frame>From baseline to Week 48</time_frame>
        <population>All patients with virologic failure assessed for genotypic resistance</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Genotypic Resistance Associated With Virologic Failure</title>
          <description>Number of treatment-emergent drug-associated substitutions in patients with virological failure up to Week 48. The total number of genotypic mutations in those patients who were virologic failures is given, not the number of patients with mutations.</description>
          <population>All patients with virologic failure assessed for genotypic resistance</population>
          <units>Number of substitutions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emtricitabine-associated substitutions at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenofovir-associated substitutions at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nevirapine-associated substitutions at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent AIDS-defining Illness</title>
        <description>Treatment-emergent AIDS-defining illness (tr.-emerg. AIDS-def.illness) including worsening during treatment</description>
        <time_frame>From baseline to Week 144</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent AIDS-defining Illness</title>
          <description>Treatment-emergent AIDS-defining illness (tr.-emerg. AIDS-def.illness) including worsening during treatment</description>
          <population>FAS</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number with tr.-emerg. AIDS-def.illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number without tr.-emerg. AIDS-def.illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350"/>
                    <measurement group_id="O2" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent AIDS-defining Illness Leading to Death</title>
        <description>Patients with an AIDS-defining illness leading to death broken out by treatment. Statistical analysis shows time to death from AIDS-defining illness.</description>
        <time_frame>From baseline to Week 144</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent AIDS-defining Illness Leading to Death</title>
          <description>Patients with an AIDS-defining illness leading to death broken out by treatment. Statistical analysis shows time to death from AIDS-defining illness.</description>
          <population>FAS</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number with AIDS-def. illness leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number without AIDS-def. illness leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373"/>
                    <measurement group_id="O2" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0403</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.461</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.220</ci_lower_limit>
            <ci_upper_limit>0.966</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipodystrophy</title>
        <description>Number of patients with AE lipodystrophy</description>
        <time_frame>From baseline to Week 144</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Lipodystrophy</title>
          <description>Number of patients with AE lipodystrophy</description>
          <population>FAS</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number with lipodystrophy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number without lipodystrophy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375"/>
                    <measurement group_id="O2" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Lipid Abnormalities</title>
        <description>Number of patients with AE elevated serum lipids (i.e. hypercholesterolaemia)</description>
        <time_frame>From baseline to Week 144</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Lipid Abnormalities</title>
          <description>Number of patients with AE elevated serum lipids (i.e. hypercholesterolaemia)</description>
          <population>FAS</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number with serum lipid abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number without serum lipid abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367"/>
                    <measurement group_id="O2" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycaemic Abnormalities</title>
        <description>Number of patients with AE elevated serum glucose</description>
        <time_frame>From baseline to Week 144</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Glycaemic Abnormalities</title>
          <description>Number of patients with AE elevated serum glucose</description>
          <population>FAS</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number with glycaemic abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number without glycaemic abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="376"/>
                    <measurement group_id="O2" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 96</title>
        <description>Treatment response is defined as a viral load (VL) &lt;50 copies/mL measured at two consecutive visits prior to Week 96 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 96.</description>
        <time_frame>From baseline to Week 96</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O4">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 96</title>
          <description>Treatment response is defined as a viral load (VL) &lt;50 copies/mL measured at two consecutive visits prior to Week 96 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 96.</description>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="376"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="253"/>
                    <measurement group_id="O4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="123"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin 12% (or 0.12 as proportion)</non_inferiority_desc>
            <p_value>0.0109</p_value>
            <p_value_desc>Test for superiority following confirmation of non-inferiority</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Analysis controlling for screening viral load and CD4+ count categories. N=373 NVP QD+BID patients and N=193 ATZ/r patients</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.097</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.171</ci_lower_limit>
            <ci_upper_limit>-0.022</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin 12% (or 0.12 as proportion)</non_inferiority_desc>
            <p_value>0.1033</p_value>
            <p_value_desc>Test for superiority following confirmation of non-inferiority</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Analysis controlling for screening viral load and CD4+ count categories. N=186 NVP QD patients and N=193 ATZ/r patients.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.072</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.158</ci_lower_limit>
            <ci_upper_limit>0.015</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin 12% (or 0.12 as proportion)</non_inferiority_desc>
            <p_value>0.0073</p_value>
            <p_value_desc>Test for superiority following confirmation of non-inferiority</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Analysis controlling for screening viral load and CD4+ count categories. N=187 NVP QD patients and N=193 ATZ/r patients.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.122</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.212</ci_lower_limit>
            <ci_upper_limit>-0.033</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 144</title>
        <description>Treatment response is defined as a viral load (VL) &lt;50 copies/mL measured at two consecutive visits prior to Week 144 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 144.</description>
        <time_frame>From baseline to Week 144</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O4">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 144</title>
          <description>Treatment response is defined as a viral load (VL) &lt;50 copies/mL measured at two consecutive visits prior to Week 144 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 144.</description>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="376"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="234"/>
                    <measurement group_id="O4" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="142"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin 12% (or 0.12 as proportion)</non_inferiority_desc>
            <p_value>0.0031</p_value>
            <p_value_desc>Test for superiority following confirmation of non-inferiority</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Analysis controlling for screening viral load and CD4+ count categories. N=373 NVP QD+BID patients and N=193 ATZ/r patients.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.117</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.194</ci_lower_limit>
            <ci_upper_limit>-0.040</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin 12% (or 0.12 as proportion)</non_inferiority_desc>
            <p_value>0.0365</p_value>
            <p_value_desc>Test for superiority following confirmation of non-inferiority</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Analysis controlling for screening viral load and CD4+ count categories. N=186 NVP QD patients and N=193 ATZ/r patients.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.096</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.186</ci_lower_limit>
            <ci_upper_limit>-0.006</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin 12% (or 0.12 as proportion)</non_inferiority_desc>
            <p_value>0.0033</p_value>
            <p_value_desc>Test for superiority following confirmation of non-inferiority</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Analysis controlling for screening viral load and CD4+ count categories. N=187 NVP QD patients and N=193 ATZ/r patients.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.139</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.231</ci_lower_limit>
            <ci_upper_limit>-0.046</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Virological Rebound With VL &gt;=50 Copies/mL After CVR (Confirmed Virological Response) at Week 24, 48, 96, 144</title>
        <description>The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL)</description>
        <time_frame>at Week 24, 48, 96, 144</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O4">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Virological Rebound With VL &gt;=50 Copies/mL After CVR (Confirmed Virological Response) at Week 24, 48, 96, 144</title>
          <description>The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL)</description>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="376"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>virologic rebound after CVR at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>virologic rebound after CVR at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>virologic rebound after CVR at Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>virologic rebound after CVR at Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Virological Rebound With VL &gt;=400 Copies/mL After CVR at Week 24, 48, 96, 144</title>
        <description>The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL)</description>
        <time_frame>at Week 24, 48, 96, 144</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O4">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Virological Rebound With VL &gt;=400 Copies/mL After CVR at Week 24, 48, 96, 144</title>
          <description>The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL)</description>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="376"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>virologic rebound after CVR at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>virologic rebound after CVR at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>virologic rebound after CVR at Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>virologic rebound after CVR at Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Virologic Failure at Week 48, 96, 144</title>
        <time_frame>at Week 48, 96, 144</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O4">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Virologic Failure at Week 48, 96, 144</title>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="376"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>virologic failure at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>virologic failure at Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>virologic failure at Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>week 48</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0: Difference in proportions = 0</non_inferiority_desc>
            <p_value>0.9784</p_value>
            <method>Cochran Chi-Squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>0.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.065</ci_lower_limit>
            <ci_upper_limit>0.066</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>week 96</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0: Difference in proportions = 0</non_inferiority_desc>
            <p_value>0.0331</p_value>
            <method>Cochran Chi-Squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>0.064</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>week 144</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0: Difference in proportions = 0</non_inferiority_desc>
            <p_value>0.0691</p_value>
            <method>Cochran Chi-Squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>0.058</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.121</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>week 48</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0: Difference in proportions = 0</non_inferiority_desc>
            <p_value>0.4585</p_value>
            <method>Cochran Chi-Squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.023</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.084</ci_lower_limit>
            <ci_upper_limit>0.038</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>week 96</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0: Difference in proportions = 0</non_inferiority_desc>
            <p_value>0.5438</p_value>
            <method>Cochran Chi-Squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>0.015</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.034</ci_lower_limit>
            <ci_upper_limit>0.064</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>week 144</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0: Difference in proportions = 0</non_inferiority_desc>
            <p_value>0.5659</p_value>
            <method>Cochran Chi-Squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>0.016</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.071</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Response (First Confirmed VL&lt;50 Copies/mL)</title>
        <description>Time to treatment response was defined as the time from start of treatment until the first measurement of the first confirmed virological response</description>
        <time_frame>baseline to week 144</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O4">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Response (First Confirmed VL&lt;50 Copies/mL)</title>
          <description>Time to treatment response was defined as the time from start of treatment until the first measurement of the first confirmed virological response</description>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="376"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.00" lower_limit="8.00" upper_limit="24.00"/>
                    <measurement group_id="O2" value="12.14" lower_limit="8.00" upper_limit="24.00"/>
                    <measurement group_id="O3" value="12.00" lower_limit="8.00" upper_limit="24.00"/>
                    <measurement group_id="O4" value="23.71" lower_limit="11.29" upper_limit="25.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.692</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.570</ci_lower_limit>
            <ci_upper_limit>0.839</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Cox regression on responders only (N=289 in Nevirapine QD+BID and N=175 in Atazanvir/ritonavir)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.630</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.519</ci_lower_limit>
            <ci_upper_limit>0.764</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Loss of Virologic Response (Rebound)</title>
        <description>Time to loss of virologic response (TLOVR) was defined as the time from start of treatment to the first measurement showing VL ≥ 50 copies/mL in the first virologic rebound, after having a confirmed virological response.</description>
        <time_frame>Baseline to week 144</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O4">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Loss of Virologic Response (Rebound)</title>
          <description>Time to loss of virologic response (TLOVR) was defined as the time from start of treatment to the first measurement showing VL ≥ 50 copies/mL in the first virologic rebound, after having a confirmed virological response.</description>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="376"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.86" lower_limit="48.43" upper_limit="144.00"/>
                    <measurement group_id="O2" value="143.21" lower_limit="0.00" upper_limit="144.00"/>
                    <measurement group_id="O3" value="143.71" lower_limit="4.29" upper_limit="144.00"/>
                    <measurement group_id="O4" value="143.00" lower_limit="119.29" upper_limit="144.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1329</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.762</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.535</ci_lower_limit>
            <ci_upper_limit>1.086</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure</title>
        <description>Treatment failure is defined as the occurrence of the first of at least one of the following events: early discontinuation of trial drug, change in ARV therapy, failure to achieve an HIV RNA count &lt; 50 copies/mL up to Visit 10 (week 48) or loss of virologic response</description>
        <time_frame>baseline to week 144</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O4">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure</title>
          <description>Treatment failure is defined as the occurrence of the first of at least one of the following events: early discontinuation of trial drug, change in ARV therapy, failure to achieve an HIV RNA count &lt; 50 copies/mL up to Visit 10 (week 48) or loss of virologic response</description>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="376"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.86" lower_limit="48.43" upper_limit="144.00"/>
                    <measurement group_id="O2" value="143.21" lower_limit="0.00" upper_limit="144.00"/>
                    <measurement group_id="O3" value="143.71" lower_limit="30.07" upper_limit="144.00"/>
                    <measurement group_id="O4" value="143.00" lower_limit="119.29" upper_limit="144.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0444</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.731</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.539</ci_lower_limit>
            <ci_upper_limit>0.992</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Calculated Glomerular Filtration Rate (GFR) at Week 48, 96 and 144</title>
        <description>Calculations based on the MDRD algorithm.</description>
        <time_frame>From baseline to Week 48, 96, 144</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Nevirapine QD+BID</title>
            <description>NVP 400mg QD or 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O4">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Calculated Glomerular Filtration Rate (GFR) at Week 48, 96 and 144</title>
          <description>Calculations based on the MDRD algorithm.</description>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients but numbers are reduced as indicated due to empty cells in analyses adjusting for baseline categories</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="376"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change baseline to week 48 (N=143, 128, 271, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.91" spread="13.93"/>
                    <measurement group_id="O2" value="-5.92" spread="17.11"/>
                    <measurement group_id="O3" value="-4.86" spread="15.52"/>
                    <measurement group_id="O4" value="-7.18" spread="15.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change baseline to week 96 (N=130, 122, 252, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.93" spread="14.33"/>
                    <measurement group_id="O2" value="-10.02" spread="17.37"/>
                    <measurement group_id="O3" value="-8.42" spread="15.92"/>
                    <measurement group_id="O4" value="-11.53" spread="15.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change baseline to week 144 (N=163, 168, 331, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.27" spread="20.65"/>
                    <measurement group_id="O2" value="-6.33" spread="17.30"/>
                    <measurement group_id="O3" value="-4.82" spread="19.06"/>
                    <measurement group_id="O4" value="-9.56" spread="17.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With &gt;= DAIDS Grade 2 Laboratory Abnormalities</title>
        <time_frame>week 148</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>NVP 400mg QD on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With &gt;= DAIDS Grade 2 Laboratory Abnormalities</title>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAIDS 2 moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAIDS 3 severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAIDS 4 potential lifethreatening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Reporting Rash of Any Severity</title>
        <description>Proportion of Patients reporting rash of any severity</description>
        <time_frame>week 148</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>NVP 400mg QD on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Reporting Rash of Any Severity</title>
          <description>Proportion of Patients reporting rash of any severity</description>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Reporting Hepatic Events of Any Severity</title>
        <description>Proportion of Patients reporting hepatic events of any severity</description>
        <time_frame>week 148</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>NVP 400mg QD on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Reporting Hepatic Events of Any Severity</title>
          <description>Proportion of Patients reporting hepatic events of any severity</description>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Reporting CNS (Central Nervous System) Side Effects of Any Severity</title>
        <description>Proportion of Patients reporting CNS (central nervous system) side effects of any severity</description>
        <time_frame>week 148</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized and treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>NVP 400mg QD on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Reporting CNS (Central Nervous System) Side Effects of Any Severity</title>
          <description>Proportion of Patients reporting CNS (central nervous system) side effects of any severity</description>
          <population>Full Analysis Set (FAS) defined as all randomized and treated patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Cholesterol Values From Baseline to Week 48, 96, 144</title>
        <description>Changes frombaseline in total cholesterol, LDL-cholesterol(LDL-c) and HDL</description>
        <time_frame>baseline to week 48, 96, 144</time_frame>
        <population>FAS, where only patients with corresponding laboratory values for the considered time point are considered</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>NVP 400mg QD on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Cholesterol Values From Baseline to Week 48, 96, 144</title>
          <description>Changes frombaseline in total cholesterol, LDL-cholesterol(LDL-c) and HDL</description>
          <population>FAS, where only patients with corresponding laboratory values for the considered time point are considered</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total cholesterol, week 48 (N=138,122,164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.28" spread="30.64"/>
                    <measurement group_id="O2" value="29.54" spread="27.33"/>
                    <measurement group_id="O3" value="20.84" spread="30.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total cholesterol, week 96 (N=124,114,147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.17" spread="33.67"/>
                    <measurement group_id="O2" value="36.87" spread="30.60"/>
                    <measurement group_id="O3" value="29.99" spread="31.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total cholesterol, week 144 (N=154,155,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.12" spread="32.77"/>
                    <measurement group_id="O2" value="30.66" spread="33.24"/>
                    <measurement group_id="O3" value="28.13" spread="32.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-c, week 48 (N=136,117,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.54" spread="24.44"/>
                    <measurement group_id="O2" value="17.70" spread="22.16"/>
                    <measurement group_id="O3" value="10.58" spread="26.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-c, week 96 (N=119,110,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.93" spread="23.44"/>
                    <measurement group_id="O2" value="21.66" spread="25.14"/>
                    <measurement group_id="O3" value="19.19" spread="25.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-c, week 144 (N=151,150,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.42" spread="26.61"/>
                    <measurement group_id="O2" value="17.95" spread="26.04"/>
                    <measurement group_id="O3" value="17.61" spread="28.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL, week 48(N=138,122,164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.06" spread="9.72"/>
                    <measurement group_id="O2" value="11.59" spread="10.95"/>
                    <measurement group_id="O3" value="3.49" spread="9.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL, week 96 (N=124,114,147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.86" spread="10.95"/>
                    <measurement group_id="O2" value="13.33" spread="12.00"/>
                    <measurement group_id="O3" value="4.74" spread="10.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL, week 144(N=154,155,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.61" spread="13.64"/>
                    <measurement group_id="O2" value="10.47" spread="15.35"/>
                    <measurement group_id="O3" value="5.73" spread="11.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Apolipoprotein Values From Baseline to Week 48, 96, 144</title>
        <description>Changes frombaseline apolipoprotein A1 &amp; B</description>
        <time_frame>baseline to week 48, 96, 144</time_frame>
        <population>FAS, where only patients with corresponding laboratory values for the considered time point are considered</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>NVP 400mg QD on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Apolipoprotein Values From Baseline to Week 48, 96, 144</title>
          <description>Changes frombaseline apolipoprotein A1 &amp; B</description>
          <population>FAS, where only patients with corresponding laboratory values for the considered time point are considered</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apolipoprotein A1, week 48 (N=134,121,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.22"/>
                    <measurement group_id="O2" value="0.23" spread="0.24"/>
                    <measurement group_id="O3" value="0.08" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apolipoprotein A1, week 96 (N=115,106,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.24"/>
                    <measurement group_id="O2" value="0.23" spread="0.25"/>
                    <measurement group_id="O3" value="0.07" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apolipoprotein A1, week 144 (N=144,140,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.24"/>
                    <measurement group_id="O2" value="0.14" spread="0.26"/>
                    <measurement group_id="O3" value="0.06" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apolipoprotein B, week 48 (N=134,120,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.17"/>
                    <measurement group_id="O2" value="0.03" spread="0.16"/>
                    <measurement group_id="O3" value="0.03" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apolipoprotein B, week 96 (N=115,106,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.16"/>
                    <measurement group_id="O2" value="-0.00" spread="0.17"/>
                    <measurement group_id="O3" value="0.03" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apolipoprotein B, week 144 (N=144,139,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.16"/>
                    <measurement group_id="O2" value="0.05" spread="0.18"/>
                    <measurement group_id="O3" value="0.03" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of hsCRP From Baseline to Week 48, 96, 144</title>
        <description>Change of hsCRP from baseline to week 48, 96, 144</description>
        <time_frame>baseline to week 48, 96, 144</time_frame>
        <population>FAS, where only patients with corresponding laboratory values for the considered time point are considered</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>NVP 400mg QD on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Change of hsCRP From Baseline to Week 48, 96, 144</title>
          <description>Change of hsCRP from baseline to week 48, 96, 144</description>
          <population>FAS, where only patients with corresponding laboratory values for the considered time point are considered</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hsCRP, week 48 (N=142,126,173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.01" spread="12.53"/>
                    <measurement group_id="O2" value="-0.67" spread="12.71"/>
                    <measurement group_id="O3" value="-0.70" spread="8.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hsCRP, week 96 (N=128,120,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.54" spread="11.21"/>
                    <measurement group_id="O2" value="-0.79" spread="21.32"/>
                    <measurement group_id="O3" value="0.35" spread="15.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hsCRP, week 144 (N=160,164,174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="14.34"/>
                    <measurement group_id="O2" value="-0.02" spread="12.76"/>
                    <measurement group_id="O3" value="0.04" spread="8.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Total Triglycerides From Baseline to Week 48, 96, 144</title>
        <description>Change of total triglycerides from baseline to week 48, 96, 144</description>
        <time_frame>baseline to week 48, 96, 144</time_frame>
        <population>FAS, where only patients with corresponding laboratory values for the considered time point are considered</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>NVP 400mg QD on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Total Triglycerides From Baseline to Week 48, 96, 144</title>
          <description>Change of total triglycerides from baseline to week 48, 96, 144</description>
          <population>FAS, where only patients with corresponding laboratory values for the considered time point are considered</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total triglycerides, week 48 (N=138,120,164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="92.39"/>
                    <measurement group_id="O2" value="1.67" spread="99.31"/>
                    <measurement group_id="O3" value="36.28" spread="80.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total triglycerides, week 96 (N=124,113,147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.34" spread="95.66"/>
                    <measurement group_id="O2" value="5.35" spread="84.92"/>
                    <measurement group_id="O3" value="30.45" spread="94.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total triglycerides, week 144 (N=153,153,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.46" spread="77.97"/>
                    <measurement group_id="O2" value="6.11" spread="80.82"/>
                    <measurement group_id="O3" value="27.11" spread="85.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Total Cholesterol to HDL-cholesterol Ratio From Baseline to Week 48, 96, 144</title>
        <description>Change of Total cholesterol to HDL-cholesterol ratio from baseline to week 48, 96, 144</description>
        <time_frame>baseline to week 48, 96, 144</time_frame>
        <population>FAS, where only patients with corresponding laboratory values for the considered time point are considered</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine QD</title>
            <description>NVP 400mg QD on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O2">
            <title>Nevirapine BID</title>
            <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
          </group>
          <group group_id="O3">
            <title>Atazanvir/Ritonavir</title>
            <description>ATZ/r on a background of the fixed combination Truvada®</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Total Cholesterol to HDL-cholesterol Ratio From Baseline to Week 48, 96, 144</title>
          <description>Change of Total cholesterol to HDL-cholesterol ratio from baseline to week 48, 96, 144</description>
          <population>FAS, where only patients with corresponding laboratory values for the considered time point are considered</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total triglycerides, week 48 (N=138,122,164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.95"/>
                    <measurement group_id="O2" value="-0.33" spread="1.05"/>
                    <measurement group_id="O3" value="0.20" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total triglycerides, week 96 (N=124,114,147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.93"/>
                    <measurement group_id="O2" value="-0.25" spread="1.03"/>
                    <measurement group_id="O3" value="0.28" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total triglycerides, week 144 (N=154,155,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.96"/>
                    <measurement group_id="O2" value="-0.07" spread="1.45"/>
                    <measurement group_id="O3" value="0.17" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>148 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nevirapine QD</title>
          <description>NVP 400mg QD on a background of the fixed combination Truvada®</description>
        </group>
        <group group_id="E2">
          <title>Nevirapine BID</title>
          <description>NVP 200mg BID on a background of the fixed combination Truvada®</description>
        </group>
        <group group_id="E3">
          <title>Atazanvir/Ritonavir</title>
          <description>ATZ/r on a background of the fixed combination Truvada®</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Myopericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Candida pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cryptococcosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug exposure during pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Fracture of penis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Bone neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cerebellar syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Breast prosthesis implantation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Mastoidectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Tympanoplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="161" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gonorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

